NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Apollomics, Inc. (APLM) Stock Analysis

Apollomics, Inc. (APLM) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

APLM

$21.59

−$0.46 (−2.06%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare APLM with… →

APLM Key Statistics

As of Oct 21, 2026
Trading
Open
$21.66
Previous Close
$22.05
Day's Range
21.58–21.76
52-Week Range
10.01–31.00
Volume
3.25K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.54
Valuation
Market Cap
$62.94M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
7.12
EPS (ttm)Profit attributable to each share over the last twelve months.
−7.57
Financials (FY)
Revenue (FY)
$8.50M
Net Income (FY)
−$10.94M
Profit marginThe share of revenue left as profit after all costs and taxes.
−123.72%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.91M
1-Year Return
−19.82%
Dividend and dates
Avg Volume
15.13K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, APLM closed at $21.59, −19.82% over 1 year.

Apollomics, Inc. (APLM) has a market capitalization of $62.94M.

In fiscal 2025, APLM reported revenue of $8.50M.

APLM Stock Return by Calendar Year

Apollomics, Inc. (APLM) return since Nov 2021: what $10,000 became

1 year
$10,000 $8,018
−19.82%
3 years
$10,000 $1,234
−87.66%
Since Nov 2021
$10,000 $218
−97.82%

If you had invested $10,000 in Apollomics, Inc. (APLM) at the close on November 26, 2021, the earliest close on record here, it would have been worth $218 at the close on October 21, 2026: −97.82% in total, −54.19% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+15.50%
2025+91.74%
2024−89.90%
2023−90.69%
2022+4.33%
2021 (partial year)+0.30%

As of October 21, 2026.

APLM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$8.50M−$10.94M−128.7%
2024$0.00−$53.86M—
2023$0.00−$172.60M—
2022$0.00−$240.81M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$8.50M—−$9.19M−$10.94M−128.7%
2024$0.00—−$42.03M−$53.86M—
2023$0.00—−$54.37M−$172.60M—
2022$0.00—−$44.39M−$240.81M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

APLM Valuation vs Biotechnology Median

Median of 608 stocks
MetricAPLMBiotechnology medianvs median
P/S ratio7.1213.3046% below
Profit margin−123.72%−38.31%85.4 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Analysis

Data-derived

Company Overview

The market values Apollomics, Inc. (APLM) at $62.94M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 14.

APLM last closed at $21.59 on October 21, 2026. That is −$0.46 (−2.06%) against the previous close. Over the past 52 weeks the price has ranged from $10.01 to $31.00. The latest close sits 115.8% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $8.50M. The same year closed with a net loss of $10.94M. The reported profit margin is −123.72%. That is 85.4 percentage points below the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to −7.57.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $8.50M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 7.12 times revenue. On price-to-sales that is 46.47% below the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.54. Annualized volatility over the trailing 4 years is 164.27%. The trailing one-year total return is −19.82%. Measured over 3 years, that is −50.22% a year compounded.

Growth & Income

The record shows no dividend for APLM.

Across the complete calendar years on file, 2025 returned +91.74% and 2023 returned −90.69%. Of the 4 complete calendar years on file, 2 finished higher. So far in 2026 the total return is +15.50%.

Peer Comparison

Apollomics, Inc. (APLM) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Apollomics, Inc. APLM $62.94M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Apollomics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Apollomics, Inc.

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment. It also develops immuno-oncology products, such as APL-501, an anti-PD-1 antibody product candidate, which is in phase 1 clinical trial for the treatment of advanced or relapsed/refractory solid tumors; APL-502, an anti-PD-L1 antibody product candidate for the treatment of tumors; APL-810, a novel, rationally designed, ACCI recombinant vaccine for the treatment of gastrin immunogen; and APL-801, a CD40 and PD-L1 antibody product candidate for the treatment of tumors. The company was founded in 2015 and is based in Foster City, California.

Visit website →